Company Profile

hair. Intercytex uses its fully integrated cell technology platform to develop living, human cell-based  products, at commercially viable scale in attractive markets.

Intercytex has four products in development:

• ICX-PRO (cyzact®), designed to stimulate active repair in chronic wounds - in Phase III trials for VLUs and Phase II trials for DFUs
  
  

• VAVELTA®, a facial rejuvenation and skin damage repair product - in Phase II efficacy trials and available from a number of specialised centres in a clinical setting only
  
  

• ICX-TRC, a hair regeneration product - in Phase II trials
  
  
• ICX-SKN, being developed as a skin graft replacement - completed Phase I trials
  
  

All Intercytex' products are derived from unmodified human cells.

Intercytex commenced operations in 2000 and currently employs around 80 staff. In addition to its head office in Cambridge, UK, it has GMP compliant clinical production facility plus research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA.

Intercytex’ shares trade on the Alternative Investment Market of the London Stock Exchange under the ticker symbol ICX.L and on the Open Market and the Xetra trading platform of the Frankfurt Stock Exchange under the symbol IGJ.F.

Corporate fact sheet